GlycoVaxyn AG
This article was originally published in Start Up
Executive Summary
Historically, the method for producing glycoconjugate vaccines has been lengthy and complex with low yields, requiring two separate fermentation runs and numerous purification steps, as well as a tedious chemical conjugation step. In contrast, GlycoVaxyn AG's vaccine conjugates are produced in recombinant E. coli using a single fermentation run that includes the conjugation process, and subsequent downstream purifications.